Assessment of the Concentration of Bone Metabolism Markers: Sclerostin and FGF-23 in Children with Idiopathic Nephrotic Syndrome Treated with Glucocorticosteroids

Table 2

The plasma concentrations of Scl and FGF-23 in the studied groups.

		Scl (ng/ml) M (25Q, 75Q) min-max	FGF-23 (pg/ml) M (25Q, 75Q) min-max
Control group ()		4.92 (4.75, 5.04) 4.46-5.21	6.93 (6.54, 7.17) 6.24-7.72
Group I ()	First occurrence	9.41 (9.18, 9.75)^a 8.90-9.78	25.9 (24.8, 26.5)^a 24.2-27.1
	Remission	9.60 (9.43, 9.75) 9.25-9.86	30.8 (30.2, 31.2) 29.6-31.7
Group II ()	Relapse	11.7 (11.3, 12.2)^a 11.1-12.2	35.4 (35.0, 37.1)^a 33.6-37.7
	Remission	—	—
Group III ()	Relapse	16.4 (16.2, 17.4)^a 15.1-18.2	89.7 (86.2, 91.9)^a 82.4-95.4
	Remission	10.79 (10.21,11.0) 9.92-11.07	81.8 (79.8, 82.7) 77.9-83.6
Group IV ()	Relapse	—	—
	Remission	14.0 (13.9, 14.2)^a 133.7-14.3	82.9 (82.2, 84.6)^a 80.2-86.2

Data are presented as median values, quartiles (first and third), and range (minimum and maximum values). ^a INS group versus the control group.